On The Horizon: Planned Filings For Novel Drugs In 2011
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
On top of the full slate of pending applications, the pool of potential novel product approvals in 2011 continues to grow as more submissions come in.
You may also be interested in...
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.
Targeted Oncologics ISO Companion Diagnostics To Find Attractive Patients
The molecularly targeted oncologics that have energized oncology drug development and treatment over the last decade have sparked a secondary boom in companion diagnostics. After all, a drug for a tumor expressing a particular receptor profile is not particularly useful unless physicians can identify patients with that profile.